216 related articles for article (PubMed ID: 29305065)
1. High macrophage PD-L1 expression not responsible for T cell suppression.
Goldman N; Lomakova YD; Londregan J; Bucknum A; DePierri K; Somerville J; Riggs JE
Cell Immunol; 2018 Feb; 324():50-58. PubMed ID: 29305065
[TBL] [Abstract][Full Text] [Related]
2. Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production.
Yamazaki T; Akiba H; Koyanagi A; Azuma M; Yagita H; Okumura K
J Immunol; 2005 Aug; 175(3):1586-92. PubMed ID: 16034097
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer.
Diskin B; Adam S; Cassini MF; Sanchez G; Liria M; Aykut B; Buttar C; Li E; Sundberg B; Salas RD; Chen R; Wang J; Kim M; Farooq MS; Nguy S; Fedele C; Tang KH; Chen T; Wang W; Hundeyin M; Rossi JAK; Kurz E; Haq MIU; Karlen J; Kruger E; Sekendiz Z; Wu D; Shadaloey SAA; Baptiste G; Werba G; Selvaraj S; Loomis C; Wong KK; Leinwand J; Miller G
Nat Immunol; 2020 Apr; 21(4):442-454. PubMed ID: 32152508
[TBL] [Abstract][Full Text] [Related]
4. Expression of programmed death 1 ligands by murine T cells and APC.
Yamazaki T; Akiba H; Iwai H; Matsuda H; Aoki M; Tanno Y; Shin T; Tsuchiya H; Pardoll DM; Okumura K; Azuma M; Yagita H
J Immunol; 2002 Nov; 169(10):5538-45. PubMed ID: 12421930
[TBL] [Abstract][Full Text] [Related]
5. PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4
Mattox AK; Lee J; Westra WH; Pierce RH; Ghossein R; Faquin WC; Diefenbach TJ; Morris LG; Lin DT; Wirth LJ; Lefranc-Torres A; Ishida E; Chakravarty PD; Johnson L; Zeng YC; Chen H; Poznansky MC; Iyengar NM; Pai SI
Cancer Res; 2017 Nov; 77(22):6365-6374. PubMed ID: 28947422
[TBL] [Abstract][Full Text] [Related]
6. PHA eludes macrophage suppression to activate CD8
Lomakova YD; Londregan J; Maslanka J; Goldman N; Somerville J; Riggs JE
Immunobiology; 2019 Jan; 224(1):94-101. PubMed ID: 30446337
[TBL] [Abstract][Full Text] [Related]
7. Anti-PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment.
Xiong H; Mittman S; Rodriguez R; Moskalenko M; Pacheco-Sanchez P; Yang Y; Nickles D; Cubas R
Cancer Res; 2019 Apr; 79(7):1493-1506. PubMed ID: 30679180
[TBL] [Abstract][Full Text] [Related]
8. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
[TBL] [Abstract][Full Text] [Related]
9. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
[TBL] [Abstract][Full Text] [Related]
10. PD-1/PD-L pathway inhibits M.tb-specific CD4
Shen L; Gao Y; Liu Y; Zhang B; Liu Q; Wu J; Fan L; Ou Q; Zhang W; Shao L
Sci Rep; 2016 Dec; 6():38362. PubMed ID: 27924827
[TBL] [Abstract][Full Text] [Related]
11. The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity.
Ostrand-Rosenberg S; Horn LA; Haile ST
J Immunol; 2014 Oct; 193(8):3835-41. PubMed ID: 25281753
[TBL] [Abstract][Full Text] [Related]
12. Macrophage regulation of B cell proliferation.
Goldman N; Valiuskyte K; Londregan J; Swider A; Somerville J; Riggs JE
Cell Immunol; 2017 Apr; 314():54-62. PubMed ID: 28238361
[TBL] [Abstract][Full Text] [Related]
13. Frequencies of PD-1- and PD-L1- positive T CD3
Nowicka D; Grywalska E; Surdacka A; Grafka A; Roliński J
Microb Pathog; 2019 Jan; 126():85-91. PubMed ID: 30342909
[TBL] [Abstract][Full Text] [Related]
14. CD4 T-cell help programs a change in CD8 T-cell function enabling effective long-term control of murine gammaherpesvirus 68: role of PD-1-PD-L1 interactions.
Dias P; Giannoni F; Lee LN; Han D; Yoon S; Yagita H; Azuma M; Sarawar SR
J Virol; 2010 Aug; 84(16):8241-9. PubMed ID: 20534854
[TBL] [Abstract][Full Text] [Related]
15. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
[TBL] [Abstract][Full Text] [Related]
16. A soluble form of CD80 enhances antitumor immunity by neutralizing programmed death ligand-1 and simultaneously providing costimulation.
Haile ST; Horn LA; Ostrand-Rosenberg S
Cancer Immunol Res; 2014 Jul; 2(7):610-5. PubMed ID: 24819296
[TBL] [Abstract][Full Text] [Related]
17. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
18. Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation.
Hartley GP; Chow L; Ammons DT; Wheat WH; Dow SW
Cancer Immunol Res; 2018 Oct; 6(10):1260-1273. PubMed ID: 30012633
[TBL] [Abstract][Full Text] [Related]
19. Forced expression of programmed death-1 gene on T cell decreased the incidence of type 1 diabetes.
Won TJ; Jung YJ; Kwon SJ; Lee YJ; Lee DI; Min H; Park ES; Joo SS; Hwang KW
Arch Pharm Res; 2010 Nov; 33(11):1825-33. PubMed ID: 21116786
[TBL] [Abstract][Full Text] [Related]
20. An optimized protocol for the in vitro generation and functional analysis of human PD1/PD-L1 signal.
Khedri M; Abnous K; Rafatpanah H; Ramezani M
J Recept Signal Transduct Res; 2018 Feb; 38(1):31-36. PubMed ID: 29252078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]